SCHEMBL15840709

SCHEMBL15840709

Cc1nc(Nc2nc(=O)cc(-c3ccccc3)[nH]2)nc2c(C)cccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
ALDH1A1 P00352 6/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HSD17B10 Q99714 3/20 0.51
MAPK1 P28482 1/20 0.51
POLB P06746 2/20 0.49
LMNA P02545 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PARP1 P09874 2/20 0.45
TNKS O95271 1/20 0.45
TNKS2 Q9H2K2 1/20 0.45
STAT3 P40763 3/20 0.45
TP53 P04637 1/20 0.45
STAT1 P42224 1/20 0.45
GAA P10253 2/20 0.44
ALPL P05186 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840830 0.81 MAPT (0.69) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840699 0.75 AURKA (0.71) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840786 0.74 MAPT (0.60) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840690 0.74 ALDH1A1 (0.55) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840712 0.73 MAPT (0.64) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL2495418 0.71 MAPT (0.49) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840587 0.71 MAPT (0.52) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840817 0.70 MAPK1 (0.70) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840687 0.70 ALDH1A1 (0.50) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10
SCHEMBL15840765 0.70 ALDH1A1 (0.52) MAPTALDH1A1KMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885KMT2A 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.